Cytosorbents Corporation
CTSO
$0.93
$0.02372.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 62.72% | 42.91% | 29.56% | 17.69% | 1.11% |
| Total Depreciation and Amortization | -20.66% | -20.75% | -13.79% | 39.35% | 61.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -146.65% | -16.39% | 199.12% | 62.73% | 227.42% |
| Change in Net Operating Assets | 116.01% | -43.03% | -276.75% | -621.12% | -506.71% |
| Cash from Operations | 53.96% | 44.12% | 33.38% | 10.18% | 3.97% |
| Capital Expenditure | 13.63% | -226.73% | 47.25% | 52.72% | 73.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -0.86% | -13.43% | 3.39% | -5.62% | -8.63% |
| Cash from Investing | 5.94% | -54.83% | 28.58% | 32.40% | 56.35% |
| Total Debt Issued | -100.00% | -- | -- | 200.00% | 200.00% |
| Total Debt Repaid | 100.00% | -600.00% | -- | -- | -- |
| Issuance of Common Stock | -45.79% | -49.44% | -98.48% | 441.75% | 699.31% |
| Repurchase of Common Stock | -21,200.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 92.71% | -- | -- | -- | -- |
| Cash from Financing | -68.81% | 26.61% | -35.53% | 194.26% | 234.40% |
| Foreign Exchange rate Adjustments | 289.46% | 38.30% | 15.13% | -156.29% | -202.60% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3,160.70% | 128.36% | 28.81% | 114.97% | 100.62% |